Oct. 6, 2020—Conformational change in a reovirus surface protein modulate the virus’s attachment to host cells, Vanderbilt researchers have found.
Sep. 22, 2020—Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development.
Sep. 17, 2020—Understanding how bacteria evolve resistance to antibiotics and host stresses could guide the development of more effective antimicrobial therapeutics.
Aug. 11, 2020—An inflammatory factor in mucus could be a biomarker of treatment-resistant chronic sinusitis used to determine which patients are at risk for repeat sinus surgery.
Aug. 6, 2020—Deborah Lannigan and colleagues identify a key regulator of the estrogen receptor and suggest that its downregulation by oral contraceptives may increase oxidative stress and DNA damage, a common cause of cancer.
Jul. 23, 2020—The H. pylori machinery that “injects” an oncoprotein into stomach cells contributes to the development of gastric cancer, Vanderbilt researchers demonstrate.
Jul. 23, 2020—A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.
Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
Jul. 13, 2020—Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.
Jul. 9, 2020—Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.